chenodeoxycholic acid has been researched along with Atherogenesis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attema, J; Caspers, MPM; de Ruiter, C; Kleemann, R; Menke, AL; Radhakrishnan, S; Salic, K; van den Hoek, AM; van Nieuwkoop, A; Verschuren, L; Worms, N | 1 |
| Escher, G; Sviridov, D; Vogt, B; Zurkinden, L | 1 |
| Sanyal, AJ | 1 |
| Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B | 1 |
| Cheng, J; Hu, H; Qu, X; Yan, W; Zhang, T; Zhou, X | 1 |
1 review(s) available for chenodeoxycholic acid and Atherogenesis
| Article | Year |
|---|---|
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Humans; Insulin Resistance; Lipid Metabolism; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2015 |
4 other study(ies) available for chenodeoxycholic acid and Atherogenesis
| Article | Year |
|---|---|
A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Fast Foods; Hyperinsulinism; Hyperlipidemias; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Transcriptome; Treatment Outcome | 2020 |
Downregulation of
Topics: Animals; Apolipoproteins E; Atherosclerosis; Chenodeoxycholic Acid; Cholestanetriol 26-Monooxygenase; Cholesterol 7-alpha-Hydroxylase; Cholesterol, HDL; Cholesterol, LDL; Cholic Acid; Diet, Western; Down-Regulation; Intestinal Absorption; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Signal Transduction | 2020 |
Antiatherosclerotic effect of farnesoid X receptor.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha | 2009 |
Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Topics: Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cells, Cultured; Chenodeoxycholic Acid; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; Macrophages; Male; Mice; Mice, Knockout; Orphan Nuclear Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Triglycerides | 2010 |